Interpace Diagnostics


Maxim Shares Two Cents on Interpace Diagnostics (IDXG) Following Expansion of Reimbursement Contract

Interpace Diagnostics (NASDAQ:IDXG) shares ticked higher today, after the pathology services and molecular diagnostic tests firm announced that Blue Cross Blue Shield of …

Maxim Comments on Interpace Diagnostics (IDXG) Following 1Q18 Update

Maxim analyst Jason McCarthy is out today with a research note on shares of Interpace Diagnostics (NASDAQ:IDXG), after the company released first-quarter results, posting $4.8 …